Saito Biotechnology: Subsidiary received European CEP certificate for chemical raw materials.

Saito Biology announced that its holding subsidiary Shandong Srui Pharmaceutical Co., Ltd. recently received a Certificate of Suitability for the European Pharmacopoeia (CEP) issued by the European Medicines Agency for the active pharmaceutical ingredient methylprednisolone. The certificate number is CEP 2024-523-Rev 00, valid for five years from March 24, 2026. The company submitted a CEP application for methylprednisolone API to the EDQM in June 2025 and obtained the certificate in March 2026. According to IQVIA data, the global demand for methylprednisolone API was approximately 40 tons in 2024. Obtaining this certificate will help the company's API to be sold in the international market, enhancing market competitiveness.